ArticleJournal of clinical pathology1992
c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
Article in Journal of clinical pathology, 1992. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 101 citations in OpenAlex.
- Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43.Breast cancer research and treatment · 2013Trial
- Clinical significance of K-ras and c-erbB-2 mutations in pancreatic adenocarcinoma and chronic pancreatitis.International journal of gastrointestinal cancer · 2005Trial
- Quantitative assessment of HER2 expression in invasive ductal carcinoma and co-existing DCIS.Breast cancer research and treatment · 2025Article
- Reduced Basal Nitric Oxide Production Induces Precancerous Mammary Lesions via ERBB2 and TGFβ.Scientific reports · 2019Article
- Niche-localized tumor cells are protected from HER2-targeted therapy via upregulation of an anti-apoptotic program in vivo.NPJ breast cancer · 2017Article
- Use of monoclonal antibody-IRDye800CW bioconjugates in the resection of breast cancer.The Journal of surgical research · 2014Article
- Article
- Protein biomarkers for the early detection of breast cancer.International journal of proteomics · 2011Article
- The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Experimental and molecular pathology · 2009Review
- The t10,c12 isomer of conjugated linoleic acid stimulates mammary tumorigenesis in transgenic mice over-expressing erbB2 in the mammary epithelium.Carcinogenesis · 2007Article
- Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.Pathology oncology research : POR · 2006Article
- HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.Breast cancer research : BCR · 2005Article
- Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines.Oncogene · 2003Article
- Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.British journal of cancer · 2001Article
- Biological features of premalignant disease in the human breast.Journal of mammary gland biology and neoplasia · 2000Review
- Fluorescence in situ hybridisation detection of erbB2 amplification in breast cancer fine needle aspirates.Molecular pathology : MP · 1999Article
- Biological indices in the assessment of breast cancer.Clinical molecular pathology · 1995Article
- ErbB-2 oncoprotein overexpression in breast carcinoma: inverse correlation with biochemically- and immunohistochemically-determined hormone receptors.Breast cancer research and treatment · 1995Article
- The need for epidemiologic studies of in-situ carcinoma of the breast.Breast cancer research and treatment · 1995Review
- Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.Breast cancer research and treatment · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess c-erbB-2 immunostaining in relation to morphological type of in situ and invasive breast carcinoma.
methodsFormalin fixed, wax embedded archival tissue was used. Invasive carcinomas comprised 50 infiltrating ductal (NOS); seven medullary, 10 tubular, 15 mucinous and 24 classic invasive lobular. In situ carcinomas comprised 48 ductal (DCIS) and 10 cases of lobular (LCIS). The antibodies used were pAB1 (polyclonal) which stains cell lines that over express the c-erbB-2 oncogene, and ICR 12 (monoclonal) which stains sections of breast carcinoma known to show c-erbB-2 amplification.
resultsImmunostaining consistent with c-erbB-2 overexpression was found in 10 out of 50 cases of infiltrating ductal carcinoma (NOS), one of 24 infiltrating lobular carcinomas and one of seven medullary carcinomas only. Seventy per cent of ICR 12 positive cases of infiltrating ductal carcinoma also had extratumoral DCIS. Forty six per cent of pure DCIS lesions also showed strong membrane staining for c-erbB-2 protein, confined to large cell types.
conclusionsImmunostaining for c-erb B-2 oncoprotein occurs mainly in large cell DCIS and infiltrating ductal carcinoma NOS, especially those with an extratumoral DCIS component. There is a low incidence in other types of breast cancer, including those associated with a better prognosis. Different biological mechanisms may be responsible for histologically distinct types of breast carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.